Related Experiment Video
Updated: Jul 17, 2025

Spectral Karyotyping to Study Chromosome Abnormalities in Humans and Mice with Polycystic Kidney Disease
Published on: February 3, 2012
DNAJA2 deficiency activates cGAS-STING pathway via the induction of aberrant mitosis and chromosome instability
Yaping Huang1, Changzheng Lu2,3, Hanzhi Wang1
1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract:
Molecular chaperone HSP70s are attractive targets for cancer therapy, but their substrate broadness and functional non-specificity have limited their role in therapeutical success. Functioning as HSP70's cochaperones, HSP40s determine the client specificity of HSP70s, and could be better targets for cancer therapy. Here we show that tumors defective in HSP40 member DNAJA2 are benefitted from immune-checkpoint blockade (ICB) therapy. Mechanistically, DNAJA2 maintains centrosome homeostasis by timely degrading key centriolar satellite proteins PCM1 and CEP290 via HSC70 chaperone-mediated autophagy (CMA). Tumor cells depleted of DNAJA2 or CMA factor LAMP2A exhibit elevated levels of centriolar satellite proteins, which causes aberrant mitosis characterized by abnormal spindles, chromosome missegregation and micronuclei formation. This activates the cGAS-STING pathway to enhance ICB therapy response in tumors derived from DNAJA2-deficient cells. Our study reveals a role for DNAJA2 to regulate mitotic division and chromosome stability and suggests DNAJA2 as a potential target to enhance cancer immunotherapy, thereby providing strategies to advance HSPs-based cancer therapy.
Insights
Tumors lacking DNAJA2 show improved responses to immune-checkpoint blockade (ICB) therapy. DNAJA2 deficiency disrupts mitosis, activating pathways that enhance cancer immunotherapy effectiveness.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Molecular chaperones like HSP70s are cancer therapy targets, but their broadness limits efficacy.
- HSP40 cochaperones, such as DNAJA2, offer client specificity and could be superior therapeutic targets.
Purpose of the Study:
- To investigate the role of DNAJA2 in cancer, particularly its impact on immune-checkpoint blockade (ICB) therapy response.
- To elucidate the molecular mechanisms by which DNAJA2 influences tumor cell biology and immune interactions.
Main Methods:
- Analysis of tumors with DNAJA2 deficiency and their response to ICB therapy.
- Investigating the role of DNAJA2 in maintaining centrosome homeostasis via chaperone-mediated autophagy (CMA).
- Assessing the impact of DNAJA2 depletion on mitotic division, chromosome stability, and the cGAS-STING pathway.
Main Results:
- Tumors deficient in DNAJA2 exhibit enhanced sensitivity to ICB therapy.
- DNAJA2 depletion leads to elevated centriolar satellite proteins (PCM1, CEP290), causing aberrant mitosis and chromosome instability.
- This mitotic dysfunction activates the cGAS-STING pathway, improving ICB therapy outcomes.
Conclusions:
- DNAJA2 plays a critical role in regulating mitotic division and chromosome stability.
- Targeting DNAJA2 or related pathways (CMA) could enhance cancer immunotherapy efficacy.
- DNAJA2 is a promising target for advancing HSP-based cancer therapies and improving treatment strategies.
Related Concept Videos
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
Anaphase Promoting Complex
Meiosis II
The timing and cell division patterns of meiosis differ between males and females. In male meiosis, the centrosomes are part of the formation of the meiotic spindle. However, in oocytes, including that of humans, Drosophila,...
Inhibition of Cdk Activity
DNA Damage Can Stall the Cell Cycle

